Canada markets open in 1 hour 5 minutes
  • S&P/TSX

    20,099.81
    +400.71 (+2.03%)
     
  • S&P 500

    4,023.89
    +93.81 (+2.39%)
     
  • DOW

    32,196.66
    +466.36 (+1.47%)
     
  • CAD/USD

    0.7736
    -0.0011 (-0.14%)
     
  • CRUDE OIL

    109.39
    -1.10 (-1.00%)
     
  • BTC-CAD

    38,361.20
    -1,200.83 (-3.04%)
     
  • CMC Crypto 200

    665.21
    -15.90 (-2.33%)
     
  • GOLD FUTURES

    1,799.80
    -8.40 (-0.46%)
     
  • RUSSELL 2000

    1,792.67
    +53.29 (+3.06%)
     
  • 10-Yr Bond

    2.9350
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,339.75
    -43.00 (-0.35%)
     
  • VOLATILITY

    29.27
    -2.50 (-7.87%)
     
  • FTSE

    7,417.83
    -0.32 (-0.00%)
     
  • NIKKEI 225

    26,547.05
    +119.40 (+0.45%)
     
  • CAD/EUR

    0.7417
    -0.0019 (-0.26%)
     

Stocks in play: Entheon Biomedical Corp.

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc., is now available for sale in Canada and the United States. Entheon, a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, via its Subsidiary HaluGen Life Sciences, has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca. Entheon Biomedical Corp shares C.ENBI are trading down $0.03 at $0.39.

Read:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting